Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Narrative)

v3.20.2
Stockholders' Deficit (Details Narrative)
1 Months Ended 3 Months Ended
Jun. 09, 2020
Dec. 23, 2019
USD ($)
Mar. 27, 2019
USD ($)
Sep. 30, 2017
USD ($)
Days
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
shares
Dec. 31, 2019
$ / shares
shares
Common stock shares authorized         10,000,000,000   10,000,000,000
Common stock par value | $ / shares         $ 0.0001   $ 0.0001
Preferred stock shares authorized         5,000,000    
Preferred stock par value | $ / shares         $ 0.01    
Common stock shares issued         9,898,936,775   9,648,936,775
Common stock shares outstanding         9,898,936,775   9,648,936,775
Stock-based compensation | $         $ 8,650  
Weighted average period         6 years 3 months 29 days    
Interest expenses | $           4,100,000  
2007 Equity Plan [Member]              
Stock-based compensation | $         8,650  
Weighted average period         6 years 29 days    
Intrinsic value of options exercisable | $         $ 0    
Subsequent Event [Member]              
Reverse stock split, description The Company's shareholders approved an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of all of the outstanding shares of the Company's common stock, at a specific ratio from 1-for-100 to 1-for-10,000, and to grant authorization to its Board of Directors to determine, in its discretion, the specific ratio and timing of the reverse split at any time on or before December 31, 2020, subject to the Board of Directors' discretion to abandon such amendment.            
Warrants [Member]              
Warrants outstanding         634,600,000,000    
Fair value of warrants | $     $ 4,100,000        
Interest expenses | $           $ 4,100,000  
Warrant expiration date           Mar. 31, 2022  
Series H Preferred Stock [Member]              
Preferred stock shares authorized         14,202   14,202
Preferred stock par value | $ / shares         $ 0.01   $ 0.01
Preferred stock shares outstanding         10   10
Preferred stock, stated value | $ / shares         $ 1,000    
Series F Convertible Preferred Stock [Member]              
Preferred stock shares outstanding         1,750,000    
Series F Convertible Preferred Stock [Member] | Genomas, Inc [Member]              
Number of common shares issued       1,750,000      
Number of common stock issued, value | $       $ 174,097      
Number of common stock issued on conversion | $       $ 14,625      
Trading days | Days       10      
Conversion of stock into shares       120      
Preferred stock price per share for unpaid dividend | $ / shares       $ 1.95      
Series K Convertible Preferred Stock [Member]              
Preferred stock shares outstanding         250,000    
Series H Preferred Stock [Member]              
Weighted average common stock price percentage         85.00%    
Series K Preferred Stock [Member]              
Preferred stock shares authorized         250,000   250,000
Preferred stock par value | $ / shares         $ 0.01   $ 0.01
Preferred stock shares outstanding         250,000   250,000
Series K Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]              
Number of shares issued upon conversion, value | $   $ 250,000          
Cumulative dividends percentage   8.00%          
Series J Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]              
Number of shares issued upon conversion, value | $   $ 250,000          
Series I-2 Preferred Stock [Member]              
Preferred stock shares outstanding         1,521.65    
Number of shares issued upon conversion, value | $         $ 250,000,000    
Number of shares converted         21.25 547.298